What is Anagenex?
Anagenex is at the forefront of biotechnology, specializing in the discovery of novel therapeutics. Its core innovation lies in a sophisticated small molecule directed evolution platform, augmented by machine learning. This technology empowers the company to identify and develop first-in-class and best-in-class small molecule medicines. Anagenex's strategic focus is on tackling challenging biological targets that have historically eluded conventional drug discovery methods, positioning it as a key player in the next wave of pharmaceutical innovation.
How much funding has Anagenex raised?
Anagenex has raised a total of $30M across 1 funding round:
Series A
$30M
Series A (2022): $30M with participation from Air Street Capital, Lux Capital, Menlo Ventures, Khosla Ventures, Obvious Ventures, and Catalio Capital Management
Key Investors in Anagenex
Air Street Capital
Air Street Capital is a venture capital firm that specializes in investing in AI-first companies, aiming to create enduring businesses with a lasting market impact. They focus on early-stage investments and actively support companies in refining their product, market, and technology strategies from inception.
Lux Capital
Lux Capital is a New York-based venture capital firm investing in early and growth-stage companies at the intersection of science and technology. Their focus spans frontier areas like AI, robotics, space, defense, biotechnology, and advanced materials, supporting companies from seed stage through IPO or acquisition.
Menlo Ventures
Menlo Ventures is a venture capital firm that invests in early and growth-stage technology companies across various sectors including enterprise software, consumer internet, fintech, and frontier tech. They actively partner with founders, often taking board roles to support companies through multiple stages of scaling.
What's next for Anagenex?
With the recent infusion of capital, Anagenex is poised for accelerated growth and the expansion of its drug development pipeline. The strategic investment signals a commitment to scaling its operations and advancing its pre-clinical candidates toward clinical trials. Investors, including prominent venture capital firms with deep expertise in life sciences and technology, are backing Anagenex's ambitious mission to revolutionize drug discovery. This funding will likely fuel further research and development, enhance its machine learning capabilities, and potentially forge strategic partnerships to bring its innovative therapies to market.
See full Anagenex company page
